Satellos Bioscience (MSLE) Net Income towards Common Stockholders (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Net Income towards Common Stockholders came in at -$9.7 million in Q1 2026, down 261.3% year-on-year from $6.0 million in Q1 2025, and down 261.3% on a QoQ basis from $6.0 million in Q1 2025.
Satellos Bioscience (MSLE) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$9.7 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 261.3% year-over-year to -$9.7 million in Q1 2026; TTM through Mar 2026 was -$3.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$25.0 million, down 23.54% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$9.7 million, down from $6.0 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for MSLE reached as high as $6.0 million in Q1 2025 and fell as low as -$9.7 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | -0.68 |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | -453.82 Mn |
| 10 | Satellos Bioscience | 184.90 Mn | 184.90 Mn | - | -9.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.70 Mn |
| Mar 31, 2025 | 6.02 Mn |